Zoledronic acid in cancer patients with bone metastases: Results of phase I and II trials

Seminars in Oncology

Volumn 28, Issue 2 SUPPL. 6, 2001, Pages 25-34

  Berenson, James R ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER; CELLULITIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EYE TOXICITY; FEVER; FLU LIKE SYNDROME; HUMAN; HYPOPHOSPHATEMIA; LEUKOPENIA; LUNG CANCER; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RIGOR; STOMATITIS;

EID: 0034993316     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.24157     Document Type: Review

References (33)

1. Correlation of neoplasms with incidence and localization of skeletal metastases
2. Natural history, prognosis, and staging of bone metastases
3. Skeletal complications of malignancy
4. Myeloma bone disease
5. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases
6. Pathophysiologic interactions in skeletal metastasis
7. Cancer and bone
8. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis
9. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma
10. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
11. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lyric bone metastases
12. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions. A randomized, placebo-controlled trial
13. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
14. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
15. Preclinical pharmacology of CGP 42'446, a new potent, heterocyclic bisphosphonate compound
16. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy - A pooled analysis of two randomized, controlled clinical trials
17. A phase I, dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone lesions
18. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease
19. Zoledronic acid reduces skeletal related events in patients with osteolytic metastases: A double-blind, randomized, dose-response study
20. Double blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
21. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
22. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind, placebo-controlled trial
23. Esophagitis associated with the use of alendronate
24. Oral bisphosphonates - A review of clinical use in patients with bone metastases
25. Biologic and therapeutic determinants of bone mineral density in multiple myeloma
26. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer
27. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy
28. Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices
29. Assessment of bone response to systemic therapy in an EORTC trial: Preliminary experience with the use of collagen cross-link excretion
30. Clinical utility of biochemical markers of bone remodeling
31. Markers of bone resorption in patients treated with pamidronate
32. High-dose intravenous pamidronate for metastatic bone pain
33. Gamma/delta T-cell stimulation by pamidronate